Pharmacogenetics in clinical practice: current level of knowledge among Flemish physicians and pharmacists

[1]  I. Cascorbi,et al.  Implementation and obstacles of pharmacogenetics in clinical practice: An international survey , 2019, British journal of clinical pharmacology.

[2]  A. Awad,et al.  Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait , 2018, PloS one.

[3]  I. Zineh,et al.  Pharmacogenetic Labeling of FDA-Approved Drugs , 2018, JACC. Basic to translational science.

[4]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[5]  H. Guchelaar,et al.  Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. , 2017, Current pharmaceutical biotechnology.

[6]  Henk-Jan Guchelaar,et al.  A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations. , 2017, Pharmacogenomics.

[7]  E. Schwartz,et al.  The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. , 2017, Personalized medicine.

[8]  Meghan MacKenzie,et al.  Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review , 2017, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[9]  Kristen K. Reynolds,et al.  The Pharmacist's Perspective on Pharmacogenetics Implementation. , 2016, Clinics in laboratory medicine.

[10]  Nizar M. Mhaidat,et al.  An evaluation of the knowledge, opinions, expectations and concerns toward pharmacogenomics among Jordanian pharmacists. , 2016, Personalized medicine.

[11]  Julia M. Barbarino,et al.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B , 2015, Pharmacogenetics and genomics.

[12]  M. Z. Salleh,et al.  Pharmacogenomics Based Practice in Malaysia: The Attitude, Knowledge and Adoption by the Healthcare Professionals , 2020 .

[13]  Janet Sultana,et al.  Clinical and economic burden of adverse drug reactions , 2013, Journal of pharmacology & pharmacotherapeutics.

[14]  B. Bernhardt,et al.  Community pharmacists' attitudes towards clinical utility and ethical implications of pharmacogenetic testing. , 2013, Personalized medicine.

[15]  Linghua Wang,et al.  From human genome to cancer genome: The first decade , 2013, Genome research.

[16]  S. Hay,et al.  G6PD deficiency: global distribution, genetic variants and primaquine therapy. , 2013, Advances in parasitology.

[17]  W Burke,et al.  Primary care physicians' knowledge of and experience with pharmacogenetic testing , 2012, Clinical genetics.

[18]  R. Verbrugge,et al.  Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.

[19]  R. Altman,et al.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 , 2012, Pharmacogenetics and genomics.

[20]  H. McLeod,et al.  Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. , 2012, Personalized medicine.

[21]  A. Dodoo,et al.  Pharmacogenetics in Ghana: reviewing the evidence. , 2011, Ghana medical journal.

[22]  Jaekyu Shin,et al.  Survey on warfarin pharmacogenetic testing among anticoagulation providers. , 2009, Pharmacogenomics.

[23]  R. Altman,et al.  Cytochrome P450 2D6. , 2009, Pharmacogenetics and genomics.

[24]  Jaekyu Shin,et al.  Pharmacogenetics: from discovery to patient care. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[25]  P. Pharoah,et al.  Genetics, Health Care and Public Policy: An Introduction to Public Health Genetics , 2007 .

[26]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[27]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[28]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[29]  Wojciech Makalowski,et al.  The human genome structure and organization. , 2001, Acta biochimica Polonica.

[30]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[31]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[32]  Lt. R. H Stimson.  The Association of Hospital Pharmacists , 1943 .